In 2011, 21 children were enrolled using email surveys alone to refine the surveillance concept. In 2012, 200 children were enrolled from 16 general

SAHA HDAC solubility dmso medical practices in Newcastle and the Children’s Hospital Westmead, Sydney. This testing resulted in: a new platform that was more mobile phone browser compatible to enhance readability and interaction on a mobile phone and an automated email to Vaxtracker team members alerting them that a serious symptom had been reported (hospitalisation and seizure). We report on the evaluation of the systems performance in the 2013 influenza seasons. In 2013, 15 large general medical practices in the Newcastle metropolitan and Tamworth rural population centres in northern NSW participated (Fig. 1). The general practice clinics were visited by a Vaxtracker staff member to demonstrate the system and answer questions. Prior to influenza vaccination, participating clinics provided parents and carers Crenolanib mouse with an information sheet (Fig. 2) on the Vaxtracker programme and they were asked

if they would like to participate. Following parental consent, clinic staff enrolled participants by entering the child’s name and their parent or carer’s contact details (email, mobile phone number or both) and brand of IIV administered into a simple secure web-based form. The Vaxtracker system automated contact with the parents or carers of immunised children by email and/or sms message to their smart phone after the child has received an influenza immunisation. Each participant was automatically contacted to complete two online surveys, the first to explore for initial reactions Cell press and a final survey to capture any late reactions. The first survey reminder was sent three days after the immunisation to facilitate timely signal detection and the final survey 42 day post-vaccination, which was considered adequate to detect rare late adverse events such as Guillain–Barré

syndrome. Participants who did not respond to the first survey did not progress to be sent the final survey on day 42. Children who receive IIV for the first time are recommended to have two doses of IIV at a one month interval [2]. These children received an automated reminder when the second IIV dose was due (one month later) and a link to the Vaxtracker survey was sent three days after the second dose due date. Participants received a link to a Vaxtracker online survey after both dose one and dose two of IIV. The online survey sent on day 3 after the first and second IIV doses was structured to collect information on 11 symptoms, while the day 42 survey for late adverse events only enquired about visits to hospital. Delayed participant survey responses were accepted until the end of the influenza season.